title: CYP1A1 and Cnr nitroreductase bioactivated niclosamide in vitro.
abstract: Niclosamide produces genotoxic effects, such as point mutations in Salmonella sp., sperm-head abnormalities in mice and clastogenic effects in human lymphocytes in vitro and in vivo. As cytochrome P450 could be involved in the bioactivation of niclosamide, we investigated which subfamily was involved. We used liver microsomal fractions from rats treated with phenobarbital/β-naphthoflavone (PB/β-NF), benzo[a]pyrene (BaP) or cyclohexanol, which are known to induce different cytochrome P450 subfamilies, such as CYP2B, CYP1A1, CYP1A2 and CYP2E1. We also inhibited CYP1A and CYP2E using α-NF and diethyldithiocarbamate to identify the cytochrome P450 involved. Liver-S9 fractions obtained from PB/β-NF- and BaP-treated rats significantly increased the number of revertants induced by niclosamide, while the CYP1A1 inhibitor α-NF decreased the number of revertants. The incubation of niclosamide with CYP1A1 Supersomes™ increased the number of revertants, suggesting that CYP1A1 is responsible for the bioactivation of niclosamide. Nitroreduction is also involved in niclosamide bioactivation, as the nitroreductase-deficient strain YG7132 did not respond to the niclosamide treatment. Our findings indicated that a metabolite, derived from the action of CYP1A1 and a nitroreduction-reaction process, has a key role in the bioactivation of niclosamide.
authors: Departamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigaciones Biomédicas and.
authors: Evelyn
authors: E
authors: Beristain-Castillo
authors: Mariano
authors: M
authors: Martínez-Vázquez
authors: Rafael
authors: R
authors: Camacho-Carranza
authors: Javier J
authors: JJ
authors: Espinosa-Aguirre
mesh_terms: D000818:Animals; D001426:Bacterial Proteins / Q000378:metabolism*; D001571:Benzoflavones / Q000494:pharmacology; D001711:Biotransformation; D019363:Cytochrome P-450 CYP1A1 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D008297:Male; D008862:Microsomes, Liver / Q000201:enzymology; D009152:Mutagenicity Tests; D009153:Mutagens / Q000378:metabolism* / Q000494:pharmacology; D009534:Niclosamide / Q000378:metabolism* / Q000494:pharmacology; D009601:Nitroreductases / Q000378:metabolism*; D010084:Oxidation-Reduction; D051381:Rats; D017208:Rats, Wistar; D012486:Salmonella typhimurium / Q000187:drug effects / Q000201:enzymology / Q000235:genetics
chemical_list: D001426:Bacterial Proteins; D001571:Benzoflavones; D009153:Mutagens; C011512:alpha-naphthoflavone; D009534:Niclosamide; D019363:Cytochrome P-450 CYP1A1; D009601:Nitroreductases
references: Mol Pharmacol. 1992 May;41(5):856-64
references: 1588920
references: Mutat Res. 1986 Jan;173(1):81-7
references: 3941681
references: Cancer Res. 1979 Oct;39(10):4206-11
references: 476655
references: Regul Toxicol Pharmacol. 2003 Feb;37(1):20-7
references: 12662906
references: Mutagenesis. 1997 May;12(3):159-62
references: 9175641
references: Biochemistry. 2009 Nov 3;48(43):10267-74
references: 19772353
references: Antimicrob Agents Chemother. 2004 Jul;48(7):2693-6
references: 15215127
references: Mutat Res. 1988 Jul;208(3-4):213-8
references: 3398871
references: Chem Res Toxicol. 2004 Aug;17(8):1077-85
references: 15310239
references: Proc Natl Acad Sci U S A. 1973 Mar;70(3):782-6
references: 4577135
references: Crit Rev Toxicol. 1986;17(1):23-60
references: 2427276
references: BMB Rep. 2011 Aug;44(8):517-22
references: 21871175
references: Mutat Res. 1988 Feb;204(2):269-76
references: 3278217
references: FEMS Microbiol Rev. 2008 May;32(3):474-500
references: 18355273
references: Int J Biochem. 1994 Dec;26(12):1333-40
references: 7890112
references: Parasitol Res. 2008 Jul;103(2):405-12
references: 18454287
references: Science. 1980 May 30;208(4447):1031-3
references: 7375915
references: Biosens Bioelectron. 2002 Dec;17(11-12):913-9
references: 12392939
references: Mutagenesis. 1992 May;7(3):175-7
references: 1602970
references: Mutat Res. 1997 Apr 14;375(1):9-17
references: 9129675
references: Proc Natl Acad Sci U S A. 1975 Mar;72(3):979-83
references: 165497
references: Curr Drug Metab. 2003 Feb;4(1):59-72
references: 12570746
references: Mutat Res. 1990 Oct;234(5):337-48
references: 2215547
references: Mutat Res. 1991 Nov;264(3):139-45
references: 1944396
references: Environ Mol Mutagen. 2005 Mar-Apr;45(2-3):106-14
references: 15688365
references: Curr Pharm Des. 2010;16(2):204-19
references: 19835560
references: Ann Intern Med. 1985 Apr;102(4):550-1
references: 3977200
references: Toxicol Appl Pharmacol. 2003 Feb 1;186(3):143-54
references: 12620367
references: Mutat Res. 1989 Aug;216(4):211-20
references: 2668749
references: Annu Rev Microbiol. 1995;49:523-55
references: 8561470
references: Am J Trop Med Hyg. 1979 Mar;28(2):300-2
references: 572147
references: Genome Biol. 2000;1(6):REVIEWS3003
references: 11178272
references: J Natl Cancer Inst. 2011 Jul 6;103(13):1018-36
references: 21685359
references: Mutagenesis. 2005 May;20(3):217-28
references: 15843387
references: Parasitol Int. 2012 Mar;61(1):52-5
references: 21864711
references: Cancer Res. 2011 Jun 15;71(12):4172-82
references: 21531761
references: Pharmacogenetics. 1999 Jun;9(3):295-306
references: 10471061
references: Mutat Res. 1983 May;113(3-4):173-215
references: 6341825
references: Drug Discov Today. 2004 Apr 1;9(7):328-36
references: 15053006
references: BMC Cancer. 2009 Jun 16;9:187
references: 19531241